Micro Innovations, Macro Opportunities
The biopharmaceutical space is ripe for innovation and investment to bring major disruption to the treatment of deathly viruses and infectious disease such as COVID-19.
The growing elderly population, prevalence of chronic diseases and adoption of biopharmaceuticals globally are impacting demand.
The increasing number of clinical trials showcase the urgent requirement for new patient solutions. Innovative biopharmaceuticals hold the key.
ACCUM™ has a proven ability to deliver treatment drugs to diseased cells. Positive outcomes against targeted vaccines points to applications globally.
R&D INVESTMENT MOMENTUM
R&D investments for new platforms, formulations and products offering have the potential for big market impact and with it, returns.
the Path Forward
With drug delivery abilities at 10x over current ADC’s, our Accum™ platform is the perfect partner for current and future drug treatments. And, with so many applications and indications Accum™ is a global solution. In combination, these pairings have the potential to become the therapeutic standard for human diseases.
Global Biopharmaceuticals Market Projections
13.8% CAGR from 2018 to 2025 vs. 3-6% for the global pharmaceuticals
Global Market Pioneers
THE GLOBAL MARKET
At 17% of the global pharmaceutical market, biopharma is projected to reach $526 Billion by 2025
This indicates biopharmaceuticals are destined to dominate the overall pharmaceutical market in the future.
Vaccines have experienced 364% revenue growth between 2007 – 2018
ANTIBODIES & ADC DOMINATED SALES
Antibodies and antibody-based agents (e.g. ADCs) dominate biopharmaceutical approvals and sales.
Antibodies were 27% of all biopharmaceutical approvals in 2010-2014 and have increased to 53% from 2016-2019.
There are 31 (15.5%) antibodies on the Top 200 selling pharmaceuticals in 2018. Five of the top 10 best selling drugs are antibodies.
Kadcyla, the ADC for breast cancer that is a standard we measure against Accum- modified ADCs produced $1 billion in sales in 2018.